B+
Bull case
30%
Probability
Target price
$50.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
EWTX
Edgewise TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.6
Score
AI commentary
As of May 9, 2026, sentiment is cautiously constructive but not emphatic. Primary company materials were positive on long-term sevasemten data and reaffirmed Q2/Q4 milestones, yet the market reaction is muted: EWTX was $35.32 at the latest checked trade versus the May 7, 2026 anchor close of $35.58, about 0.7% lower. No trustworthy post-print analyst revision wave or clear consensus beat/miss dataset was confirmed in checked sources, so this still reads as a monitoring-style setup rather than a fully validated post-earnings rerating.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventCIRRUS-HCM 12-week Part D data due in Q2 2026High impact
Management said 12-week CIRRUS-HCM data for EDG-7500 in obstructive and nonobstructive HCM are expected in Q2 2026, making this the nearest high-impact readout from the May 7, 2026 earnings update [#8-K-2026-05-07].
2026-09-30catalystHFpEF expansion could broaden the EDG-15400 story in 2H 2026High impact
Edgewise said it expects to initiate a Phase 2 HFpEF trial for EDG-15400 in the second half of 2026, which could expand the cardiovascular narrative beyond HCM if execution stays on track [#8-K-2026-05-07].
2026-12-31catalystGRAND CANYON pivotal Becker readout remains the core value driverHigh impact
The company reiterated that pivotal GRAND CANYON top-line results for sevasemten in Becker muscular dystrophy are expected in Q4 2026; this remains the main thesis-changing catalyst and potential path toward a first marketing application [#8-K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology